Profile data is unavailable for this security.
About the company
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
- Revenue in USD (TTM)3.34m
- Net income in USD-7.35m
- Incorporated2002
- Employees6.00
- LocationDyadic International Inc1044 NORTH U.S. HIGHWAY ONE, SUITE 201JUPITER 33477United StatesUSA
- Phone+1 (561) 743-8333
- Fax+1 (561) 743-8343
- Websitehttps://dyadic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncotelic Therapeutics Inc | 0.00 | -1.67m | 27.82m | 26.00 | -- | 3.06 | -- | -- | -0.0041 | -0.0041 | 0.00 | 0.0206 | 0.00 | -- | -- | 0.00 | -7.00 | -20.78 | -19.04 | -43.80 | -- | -- | -- | -1,590.30 | -- | -0.5591 | 0.632 | -- | -100.00 | -- | 42.76 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -56.98m | 29.38m | 36.00 | -- | 27.15 | -- | -- | -1.22 | -1.22 | 0.00 | 0.0194 | 0.00 | -- | -- | 0.00 | -48.20 | -42.95 | -55.60 | -46.33 | -- | -- | -- | -- | -- | -- | 0.943 | -- | -- | -- | -81.07 | -- | 36.12 | -- |
| Passage Bio Inc | 0.00 | -45.26m | 29.63m | 60.00 | -- | 0.952 | -- | -- | -14.47 | -14.47 | 0.00 | 9.79 | 0.00 | -- | -- | 0.00 | -48.69 | -49.32 | -61.70 | -53.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.54 | -- | -54.23 | -- |
| Rein Therapeutics Inc | 0.00 | -58.89m | 29.97m | 11.00 | -- | 24.19 | -- | -- | -2.63 | -2.63 | 0.00 | 1.84 | 0.00 | -- | -- | 0.00 | -74.57 | -64.62 | -80.38 | -71.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.71 | -- | -- | -- |
| VolitionRX Ltd | 1.47m | -22.88m | 30.09m | 85.00 | -- | -- | -- | 20.44 | -0.229 | -0.229 | 0.0147 | -0.316 | 0.1539 | -- | 4.74 | 17,317.88 | -241.07 | -122.29 | -- | -283.19 | -- | -- | -1,566.40 | -5,826.45 | -- | -15.03 | -- | -- | 59.10 | 135.30 | 23.65 | -- | 2.34 | -- |
| Palatin Technologies Inc | 8.85m | -4.81m | 30.12m | 29.00 | -- | 41.40 | -- | 3.40 | -13.52 | -13.52 | 12.39 | 0.4073 | 1.47 | -- | -- | 305,087.90 | -79.90 | -79.95 | -- | -118.70 | 0.00 | 91.70 | -54.32 | -1,326.05 | -- | -- | 0.00 | -- | -100.00 | -- | 41.80 | -- | -- | -- |
| Dyadic International Inc | 3.34m | -7.35m | 30.14m | 6.00 | -- | 11.56 | -- | 9.02 | -0.2371 | -0.2371 | 0.1077 | 0.072 | 0.2974 | -- | 5.27 | 557,033.30 | -65.38 | -46.12 | -89.89 | -51.96 | 31.54 | 35.01 | -219.86 | -335.59 | -- | -34.44 | 0.6579 | -- | 20.58 | 15.77 | 14.51 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -33.99m | 30.14m | 22.00 | -- | 0.4987 | -- | -- | -1.13 | -1.13 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -41.21 | -53.41 | -45.91 | -58.50 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.72 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -8.66m | 30.29m | 15.00 | -- | -- | -- | -- | -0.361 | -0.361 | 0.00 | -0.0211 | 0.00 | -- | -- | 0.00 | -491.23 | -145.64 | -- | -198.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.02 | -- | -15.59 | -- |
| Harvard Apparatus Regenertv Tchnlgy Inc | 743.00k | -6.53m | 30.39m | 8.00 | -- | 19.56 | -- | 40.90 | -0.4029 | -0.4029 | 0.0459 | 0.0905 | 0.1891 | 9.21 | 371.50 | 92,875.00 | -166.09 | -292.39 | -227.59 | -1,068.06 | 16.29 | -- | -878.20 | -6,677.86 | 1.83 | -- | 0.00 | -- | 317.48 | -- | 14.30 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -29.28m | 30.76m | 6.00 | -- | 3.35 | -- | -- | -18.62 | -18.62 | 0.00 | 4.27 | 0.00 | -- | -- | -- | -127.41 | -85.65 | -188.18 | -145.08 | -- | -- | -- | -3,184,250.00 | -- | -- | 0.00 | -- | -- | -- | 121.03 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings Inc | 0.00 | -22.76m | 30.92m | 14.00 | -- | 5.60 | -- | -- | -0.4722 | -0.4722 | 0.00 | 0.0472 | 0.00 | -- | -- | 0.00 | -207.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.79 | -- | -- | -- |
| Outlook Therapeutics Inc | 1.51m | -62.42m | 30.94m | 17.00 | -- | -- | -- | 20.55 | -1.61 | -1.61 | 0.0432 | -0.5973 | 0.0635 | -- | -- | 88,548.23 | -263.36 | -240.08 | -- | -- | 70.78 | -- | -4,146.95 | -22,354.50 | 0.3067 | -200.54 | -- | -- | -- | -- | 17.17 | -- | -- | -- |
| Cell Source Inc | 0.00 | -6.57m | 31.35m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -36.05m | 31.93m | 24.00 | -- | 1.69 | -- | -- | -10.40 | -10.40 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -141.49 | -63.01 | -215.46 | -80.57 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -41.88 | -- | 1.85 | -- |
Data as of Feb 11 2026. Currency figures normalised to Dyadic International Inc's reporting currency: US Dollar USD
13.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Apis Capital Advisors LLCas of 30 Sep 2025 | 1.54m | 4.26% |
| Chapin Davis, Inc. (Investment Management)as of 31 Dec 2025 | 888.00k | 2.45% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 768.10k | 2.12% |
| Perkins Capital Management, Inc.as of 31 Dec 2025 | 344.41k | 0.95% |
| Truist Advisory Services, Inc.as of 31 Dec 2025 | 326.20k | 0.90% |
| Geode Capital Management LLCas of 30 Sep 2025 | 265.41k | 0.73% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 251.37k | 0.70% |
| Northeast Financial Consultants LLCas of 30 Jun 2025 | 250.00k | 0.69% |
| Corient Private Wealth LLCas of 30 Sep 2025 | 250.00k | 0.69% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 165.10k | 0.46% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
